ANTCHAIN
1.11.2021 07:05:09 CET | Business Wire | Press release
Blockchain Association Singapore (BAS) today signed a Memorandum of Understanding (MOU) with AntChain, the flagship technology brand of Ant Group to form close collaborations to promote and drive further blockchain adoption and innovation in Singapore and ASEAN.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211031005054/en/
Under the partnership, BAS and AntChain will co-organize events and programs in Singapore and China to raise further awareness of blockchain, to drive industry adoption and promote positive impact through continuous innovation, and to strengthen the ecosystem of talents and empower the community through training and knowledge sharing.
The MOU with BAS is the first such industry partnership for AntChain outside China.
Commenting on the partnership, Mr Chia Hock Lai, Co-Chairman, BAS said, “We recognize AntChain’s market leadership as demonstrated through its innovative solutions and a vast range of industry applications and use cases from supply chain finance, cross border traceability of high value goods, to content and copyright protection. Thus, it is an absolute pleasure to collaborate closely with AntChain, which we believe will bring valuable technical know-how and industry experience to BAS’s members and partners in Singapore and the region. Together, more blockchain innovations can be fostered to contribute to the growth and transformation of businesses and industries.”
Mr Derrick Loi, General Manager of International Business, Intelligent Technology at Ant Group, echoed, “We firmly believe that partnerships and collaborations stimulate innovation. We are committed to working closely with industry partners such as BAS to explore new synergies, resolve pain points faced by businesses, and uncover greater value for a broader group of customers in today's digital economy. We very much look forward to enabling trusts in use cases such as digital trade, thereby connecting B2B2C with industry specific applications of enterprise blockchain, secure computing, IoT, eKYC, and other innovative technologies.”
In recent months, BAS has also formed partnerships with Alliance of Blockchain Industry (ABI) and the Energy Research Institute of the Nanyang Technological University respectively, to collaborate in various aspects to promote blockchain application, research and talent development.
In June, AntChain launched a developer community support program at its first developer conference. To date, the community has attracted over 330 institutional partners and nearly 10,000 developers, who together have created over 30 innovative industry applications. Now AntChain's wide portfolio of technologies and solutions have been deployed in more than 50 use cases, typically involving multi-party collaborations.
+++
About Blockchain Association Singapore
The Blockchain Association Singapore (BAS) seeks to empower its members and the community to leverage blockchain and scalable technologies for business growth and transformation. The Association is designed to be an effective platform for members to engage with multiple stakeholders – both regional and international – to discover solutions and promote best practices in a collaborative, open, and transparent manner.
It aims to promote blockchain literacy and build a strong talent pipeline for the digital economy in Singapore. BAS also aims to accelerate the development of blockchain companies operating in or entering into Singapore, and their subsequent integration and acceleration into the Singapore blockchain ecosystem.
For more information, please visit https://singaporeblockchain.org/ .
About AntChain
As the flagship technology brand of Ant Group, AntChain is dedicated to building the foundations of trust with innovative technologies including blockchain, the internet of things, data analytics, and intelligent risk management. It aims to develop mutually trusted, highly efficient industry based solutions to enable trust between enterprises and their customers in the new digital economy, support industry collaboration and value creation. AntChain was ranked first in China's blockchain-as-a-service market in 2020, according to market intelligence provider IDC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211031005054/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom